Following the European Medicines Agency’s approvals of the PDE-4 inhibitor Otezla and the IL-17 inhibitor Cosentyx for psoriatic arthritis (PsA), treatment of this disease in the EU5 has begun to…
The tumor necrosis factor (TNF) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. However, several…
The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…
PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF…
Two of the largest pharmacy benefits managers (PBMs) in the United States, Express Scripts and CVS Health, have set traditional U.S. drug reimbursement on its head by introducing indication-…
The algorithms for treating psoriatic arthritis ( PsA ) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…
PsA, a disease hallmarked by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF-α…
The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting…
Introduction: The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars…
For the estimated 1.6 million people in the United States who suffer from psoriatic arthritis (PsA), there are multiple prescription therapies that are available for treating the associated joint…
Where Are the Remaining Areas of Opportunity for Emerging Non-TNF Biologics and Oral Agents in the Increasingly Crowded Psoriatic Arthritis Market? The availability of tumor necrosis factor alpha…
Psoriatic arthritis (PsA) is an inflammatory joint disease that denotes a heterogeneous group of arthritides that may be present with or without obvious psoriatic lesions; therefore, treatment is…
Psoriatic arthritis (PsA) is a disease hallmarked by psoriatic skin lesions and erosive joint damage that remains poorly understood, underdiagnosed, and undertreated. Nevertheless, tumor necrosis-…
This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…